Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer
this single arm，open-label，multi-center study is aimed to evaluate the efficiency of icotinib in plasma ctDNA EGFR mutation-positive patients diagnosed with lung cancer
Plasma EGFR Mutation-positive Lung Cancer
DRUG: Icotinib
ORR, Objective Response Rate, 12 weeks
PFS, Progression-free survival, 12 months|DCR, disease control rate, 12 months|OS, overall survival, 20 months
this single arm，open-label，multi-center study is aimed to evaluate the efficiency of icotinib in plasma ctDNA EGFR mutation-positive patients diagnosed with lung cancer